指南与共识临床试验与 GCP医学人工智能与信息学

美国卫生系统实施REMAP-COVID试验的经验与建议

Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.
指南 / 共识 · Trials · 2021-01-28

本文介绍REMAP-COVID适应性平台试验在美国UPMC卫生系统首个站点的实施经验,聚焦领导参与、试验嵌入、远程知情同意与入组、监管合规、试验管理流程修改及与其他COVID-19研究协调六个方面,并提出可在其他站点推广的实施建议。

要点

  • 将试验流程嵌入常规诊疗、机构结构和电子健康记录可提升效率并促进临床与科研整合。
  • 远程知情同意与入组可通过床旁人员参与和机构视频会议工具实现。
  • 建立集中化机构流程可优化COVID-19研究的协调。

核心结论

  • 在美国大型医疗系统内实施REMAP-COVID试验是可行的,多学科协作促进了实施。
  • 该投入为未来学习型卫生系统的建设奠定了基础。

研究设计与样本

  • REMAP-COVID是一项针对COVID-19住院患者的全球适应性平台试验。
  • 本文描述该试验在美国首个站点UPMC卫生系统的实施经验,并总结六个重点实施领域。

主要发现

  • 建议对齐机构与试验目标,并将REMAP-COVID实施视为学习型卫生系统建设的基础。
  • 将试验流程嵌入常规诊疗、现有机构结构和电子健康记录可促进效率及临床与科研整合。
  • 远程知情同意与入组可通过床旁人员参与和机构视频会议工具促进。
  • 与中心机构审查委员会协调可加快审批流程。
  • 方案依从性、不良事件监测及数据收集与导出可通过构建电子健康记录流程促进,但实施初期可使用传统临床试验工具。

临床怎么用

  • 在大型卫生系统内实施平台试验时,应优先对齐机构与试验目标并推动多学科协作。
  • 将试验流程嵌入常规诊疗和电子健康记录,以提升实施效率并促进临床与科研整合。
  • 利用床旁人员和机构视频会议工具开展远程知情同意与入组。
  • 与中心机构审查委员会协调以加快审批,并建立集中化机构流程协调COVID-19研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial is a global adaptive platform trial of hospitalized patients with COVID-19. We describe implementation at the first US site, the UPMC health system, and offer recommendations for implementation at other sites. METHODS: To implement REMAP-COVID, we focused on six major areas: engaging leadership, trial embedment, remote consent and enrollment, regulatory compliance, modification of traditional trial management procedures, and alignment with other COVID-19 studies. RESULTS: We recommend aligning institutional and trial goals and sharing a vision of REMAP-COVID implementation as groundwork for learning health system development. Embedment of trial procedures into routine care processes, existing institutional structures, and the electronic health record promotes efficiency and integration of clinical care and clinical research. Remote consent and enrollment can be facilitated by engaging bedside providers and leveraging institutional videoconferencing tools. Coordination with the central institutional review board will expedite the approval process. Protocol adherence, adverse event monitoring, and data collection and export can be facilitated by building electronic health record processes, though implementation can start using traditional clinical trial tools. Lastly, establishment of a centralized institutional process optimizes coordination of COVID-19 studies. CONCLUSIONS: Implementation of the REMAP-COVID trial within a large US healthcare system is feasible and facilitated by multidisciplinary collaboration. This investment establishes important groundwork for future learning health system endeavors. TRIAL REGISTRATION: NCT02735707 . Registered on 13 April 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations. Trials. 2021. PMID: 33509275. doi:10.1186/s13063-020-04997-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。